Journal Article

Validation of the NAT Chagas IVD Kit for the Detection and Quantification of ITrypanosoma cruzi/I in Blood Samples of Patients with Chagas Disease

Jacomasso, Thiago, dos Santos, Carolina Messias, Moreira, Otacilio C, Britto, Constança, Fernandes, Alice Gomes, Krieger, Marco Aurelio, Morello, Luis Gustavo, Marchini, Fabricio Klerynton, Nascimento, Lucas de O. Rossetti, Costa, Alexandre Dias Tavares, Gomes, Natalia Lins da Silva, do Brasil, Pedro Emmanuel Alvarenga Americano, Hasslocher-Moreno, Alejandro Marcel

2023

Overview

In the absence of validated biomarkers to control the cure of Chagas disease, PCR-based diagnosis is being used as the main tool for an early indication of therapeutic failure. However, since it is considered a technique of complex reproducibility, mainly due to difficulties in establishing accurate controls to guarantee the quality of the reaction, the use of PCR for Chagas disease diagnosis is restricted to specialized centers. In an effort to disseminate the molecular diagnosis of Chagas disease and its applications, new diagnostic kits based on qPCR have been made available in the market in recent years. Here, we show the results of the validation of the NAT Chagas kit (Nucleic Acid Test for Chagas Disease) for the detection and quantification of T. cruzi in blood samples of patients suspected of Chagas disease infection. The kit, composed of a TaqMan duplex reaction targeting the T. cruzi satellite nuclear DNA and an exogenous internal amplification control, presented a reportable range from 10[sup.4] to 0.5 parasite equivalents/mL and a limit of detection (LOD) of 0.16 parasite equivalents/mL of blood. In addition, the NAT Chagas kit detected T. cruzi belonging to all six discrete typing units (DTUs—TcI to TcVI), similarly to the in-house real-time PCR performed with commercial reagents, which has been selected as the best performance assay in the international consensus for the validation of qPCR for Chagas disease. In the clinical validation presented here, the kit showed 100% sensitivity and 100% specificity when compared to the consensus in-house real-time PCR assay. Thus, the NAT Chagas kit, which is produced entirely in Brazil under the international standards of good manufacturing practices (GMP), appears as an excellent alternative to enable the molecular diagnosis of Chagas disease in public and private diagnostic centers, as well as to facilitate the monitoring of patients under etiological treatment participating in clinical trials.

• Publisher: MDPI AG
• Subject: Blood / Chagas' disease / Comparative analysis / Diagnosis / Ethylenediaminetetraacetic acid / Medical examination